NCT05620732招募中不适用
Efficacy and Safety of Claudin18.2CAR-T in Advanced Pancreatic Cancer and Gastric Carcinoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- AE/SAE
研究概览
简要总结
The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors.
详细描述
The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved.
Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors.
Investigators aim to testify to the safety and efficacy of Claudin18.2CAR-T cells in advanced pancreatic cancer and gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 (≥ 18, ≤ 75), regardless of gender;
- •Subjects voluntarily participate in the study, and they or their legal guardians sign the Informed Consent Form;
- •Non resectable, locally late recurrent or metastatic gastric cancer or pancreatic cancer confirmed by histopathology; Patients with gastric cancer or pancreatic cancer diagnosed as stage III or IV according to the TNM staging system of the American Joint Commission on Cancer (AJCC) (8th edition in 2017);
- •According to RECIST 1.1 standard, there are clearly measurable and evaluable lesions;
- •Immunohistochemical staining confirmed that Claudin 18.2 was moderately and highly expressed in tumor tissues;
- •Subjects must have received the first and second line standard treatment scheme;
- •The subject must not be suitable for receiving radical treatment methods, such as radical chemotherapy and radiotherapy and/or surgery/immunosuppressant at the checkpoint, or refuse surgical resection
- •Within 2 weeks before cell therapy, no antibody drugs were used;
- •ECOG score is 0-2;
- •The subjects had no contraindication for peripheral blood collection;
- •The expected survival period is more than 3 months.
排除标准
- •People who have a history of allergy to any component in cell products;
- •The following conditions occur in blood routine examination: WBC ≤ 1 × 109/L, absolute value of central granulocyte ANC ≤ 0.5 × 109/L, absolute value of lymphocyte ALC ≤ 0.5 × 109/L , PLT≦25 × 109/L ；
- •The following conditions occur in laboratory testing: including but not limited to, total serum bilirubin ≥ 1.5mg/dl; Serum ALT or AST is more than 2.5 times of the upper limit of normal; Blood creatinine ≥ 2.0mg/dl;
- •According to the NYHA cardiac function grading standard, patients with cardiac insufficiency belong to Grade III or IV; Or left ventricular ejection fraction (LVEF)<50% by echocardiography;
- •Pulmonary function is abnormal, and the saturation of blood oxygen under indoor air is less than 92%;
- •Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other serious heart diseases clinically within 12 months before enrollment;
- •Grade 3 hypertension and poor blood pressure control after drug treatment;
- •Have suffered from brain trauma, consciousness disorder, epilepsy, relatively serious cerebral ischemia or cerebral hemorrhage disease in the past;
- •Patients with autoimmune diseases, immunodeficiency or other patients requiring immunosuppressive treatment;
- •There is uncontrolled active infection;
- •Have used any CAR-T cell product or other genetically modified T cell therapy before;
- •Live vaccine inoculation within 4 weeks before enrollment;
- •HIV, HBV, HCV and TPPA/RPR positive persons, and HBV carriers;
- •Subjects have a history of alcohol abuse, drug abuse or mental illness;
- •Subjects have participated in any other clinical research within 3 months before joining this clinical research;
- •Female subjects have any of the following conditions: a) are in pregnancy/lactation; Or b) having a pregnancy plan during the trial; Or c) is fertile and unable to take effective contraceptive measures;
- •The investigator believes that there are other circumstances that are not suitable for the subject to participate in this study
结局指标
主要结局
AE/SAE
时间窗: From date of infusion to 30 days after infusion
adverse events/ severe adverse events
次要结局
- ORR(From admission to the end of follow up, up to 2 years.)
研究者
YuLi
Professor
Shenzhen University General Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic CancerPancreatic Ductal AdenocarcinomaNCT04827953Nelum Corp28
已完成
1 期
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic CancerPancreatic CancerNCT01663272University of Michigan Rogel Cancer Center12
已完成
2 期
A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic CancerPancreas AdenocarcinomaAdvanced Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic AdenocarcinomaPancreatic CancerNCT03331562Translational Genomics Research Institute24
Unknown
3 期
The Efficacy and Safety of a Compound Glutamine Capsule in the Prevention of Chemotherapy-induced MucositisMucositisChemotherapeutic ToxicityNCT04988971Meng Qiu90
Unknown
3 期
The Efficacy and Safety of a Compound Glutamine Capsule in the Primary Prevention of Chemotherapy-induced MucositisMucositisChemotherapeutic ToxicityNCT05092113Meng Qiu108